Introduction
It is estimated that as of 2014, 25% of people living with HIV in the United States were women. 1 Access to accurate contraceptive method information and a full range of effective options is important for HIV-infected women not only to prevent unintended pregnancy, but also to prevent vertical transmission of HIV. According to the US Medical Eligibility Criteria for Contraceptive Use (MEC), 2 all contraceptive methods are considered safe or generally safe for use by HIV-infected women. Further, concern regarding drug interactions may limit providers from recommending hormonal contraceptives. In contrast, the most recent US MEC guidelines do not recommend limiting any contraceptives based on antiretroviral therapy (ART) use. An exception to this recommendation is the infrequently prescribed protease inhibitor fosamprenavir. For women using fosamprenavir, current recommendations state that the risks of combined hormonal contraception outweigh the benefits. 3 HIV-infected individuals are encouraged by their providers to use condoms to prevent HIV transmission to uninfected partners. While there is increasing use of effective prescription contraceptive methods in the general population, 2 specifically long-acting reversible contraceptives (LARC) (which include intrauterine devices [IUDs] and implants), some data suggested that women with HIV are more likely to use less effective contraceptive options such as condoms. 4 High rates of female sterilization 2 and reduced overall pregnancy rates during early stages of the HIV epidemic may not have continued. Among women with HIV, ARTuse has increased due to efforts to improve access to testing and ART and guidelines suggesting earlier initiation of ART. 5 Due to increasing ART use, improved health outcomes, and the lower perceived HIV transmissibility associated with viral load suppression, the trends in contraceptive use among HIV-infected women may be becoming more similar to those among noninfected women. Original Research ajog.org
Our aim was to evaluate prescription contraceptive use among HIV-infected women compared to noninfected women in the United States in 2008 and 2014. Specifically, we aimed to examine differences in the pattern of prescription contraceptive methods based on HIV infection status and to explore the impact of ART use on contraceptive method use. This information will provide contemporary contraceptive trends and explore the associations between HIV and ART use and contraceptive practice patterns.
Materials and Methods
We analyzed data from the Truven Health MarketScan Commercial Claims and Encounters databases. These databases consist of a large convenience sample of individuals with employerbased health insurance and include individual-level health care claims information from employer health plans with both inpatient and outpatient diagnoses and procedure codes and links to filled outpatient prescription drug claims. All claims for a particular individual can be linked even if the employer changes insurance plans, but may not be linked if the individual changes employment. The average number of female enrollees in the database is approximately 11.4 million per year in years 2003 through 2008 and approximately 24 million per year in years 2009 through 2014. These databases undergo quality assessments to maintain validity of the data. 6 As the databases are deidentified, the institutional review board of the Centers for Disease Control and Prevention determined that this was not human subjects research.
We Our primary exposures of interest were HIV infection status and ART use (among HIV-infected women). HIV infection was defined by meeting 1 of the following 4 criteria: (1) 2 outpatient visits with HIV diagnosis codes separated by 30 days; (2) 1 outpatient diagnosis code for HIV and at least 1 antiretroviral drug (see list in Appendix of ART medications considered; medications typically used for preexposure or postexposure prophylaxis without concomitant other ART medication were excluded); (3) 2 pharmacy charges for at least 1 ART separated by 30 days; or (4) 1 inpatient stay with HIV diagnosis code. We defined HIV-infected women as ART users if they filled at least 1 prescription for ART (drug names listed in Appendix) during the 6 years of the cohort.
Our primary outcome of interest was female sterilization or reversible prescription contraceptive use during the index year. This was identified from inpatient, outpatient, and pharmaceutical databases using ICD-9-CM diagnosis and procedure codes, Healthcare Common Procedure Coding System supply codes, Current Procedural Terminology codes, and the US Food and Drug Administration National Drug Codes. We considered prescriptions to be a proxy measure for actual use. Contraceptive methods examined included female sterilization and reversible prescription methods such as IUDs, implants, injectables, pills, patches, and rings. A woman was identified as sterilized if a sterilization code was present in the inpatient or outpatient databases in the 6 years of the cohort. A woman was considered to be an IUD user during the index year if the method was placed based on a procedure code or supply code from the inpatient or outpatient databases during that index year or within the 5 years prior without a removal code noted. A woman was considered to be an implant user during the index year if the method was placed based on a procedure code or supply code from the inpatient or outpatient databases during that index year or within 3 years prior without a removal code noted. We searched for codes in the index year indicating injectable, pill, patch, or ring use. These methods needed to be identified at least once during the index year to be considered as use during that year. Injectable use was identified from inpatient and outpatient claims if there was a depot medroxyprogesterone acetate supply code or a family planning encounter diagnosis code coupled with a generic injection procedure code. Use of oral contraceptive pills (including combined and progestin-only pills), combination hormonal patches, or combination vaginal rings was identified by National Drug Codes in the pharmaceutical databases. If there were no sterilization or contraceptive codes identified, the individual was classified as using no method. Individuals classified as using no method may have been using nonprescription methods such as condoms. We used a method of hierarchal classification to determine the most effective method of contraceptive used similar to one previously described. 7 We collapsed the methods into 4 categories to evaluate trends in method use: (1) female sterilization; (2) LARC method (IUDs and implants); (3) short-acting hormonal contraception (SAHC), including shorter-acting prescription methods (injectable, pills, patch, or ring); and (4) no prescription method.
For covariates, we included age (3 categories: 15-24, 25-35, 36-44 years), region in the United States (defined as the following 5 categories by Truven Health: Northeast, North Central, South, West, unknown), chronic ajog.org GYNECOLOGY Original Research medical condition, and pregnancy. We identified women as having a chronic medical condition if they had 1 of the following conditions that were identified by the US MEC as: (1) conditions with increased health risks from an intended pregnancy; or (2) conditions for which certain contraceptives are considered unsafe or the risks outweigh the benefits. 6 The 22 chronic conditions included: diabetes, hypertension, epilepsy, breast cancer, endometrial cancer, ovarian cancer, tuberculosis, sickle cell disease, systemic lupus erythematosus, cirrhosis, thrombogenic mutations, schistosomiasis with fibrosis of liver, liver cancer, gestational trophoblastic disease, ischemic, heart disease, valvular heart disease, stroke, transplant, peripartum cardiomyopathy, bariatric surgery, and migraines (without or without aura). We used ICD-9-CM diagnosis and procedural codes to identify these conditions. Utilizing a methodology similar to one previously published, [7] [8] [9] we classified women as having a medical condition during the index year if related codes were present during 5 years prior to that year. To improve specificity and avoid overdiagnosis, we considered an individual as having the condition if there were 2 outpatient codes present at least 30 days apart (with the exception of migraines for which only 1 outpatient code was needed) or 1 inpatient code. Pregnancies (either current pregnancy or recent pregnancy with a pregnancy outcome) were identified if they had a diagnosis or procedure code for 1 of the following outcomes during the index year: any pregnancy, delivery, ectopic, molar pregnancy, or abortion (spontaneous or induced).
All statistical analyses were performed with SAS (Version 9.3; SAS Institute Inc, Cary, NC) or SUDAAN (Version 11.0.0, RTI International, Research Triange Park, NC). We generated descriptive statistics for contraceptive use and covariates with corresponding numbers and percentages. In cases where cell counts were <5, the numbers and corresponding percentages were not reported to protect individual-level data. If it was possible to calculate one of the suppressed cells with counts <5 from the 
Results
In 2008, 499,197 women were included, with 268 (0.05%) meeting our criteria for being HIV-infected. In 2014, 1,083,864 women were included with 917 (0.08%) meeting our criteria for being HIV-infected (Table 1) . There were 90,916 women represented in both cohorts. In both 2008 and 2014, the HIV-infected women were older and had more chronic medical conditions than noninfected women with 39.2% and 42.5% of the HIV-infected women having a chronic medical condition in 2008 and 2014, respectively. Among HIV-infected women, there was no significant increase in the percent of pregnancies from 2008 (5.6%) through 2014 (7.5%) There were also no significant differences in the percent of pregnancies between HIV-infected and noninfected women in either year.
Overall, the majority of women did not use female sterilization or a (Table 3 ). In 2014 there was significantly lower proportion of women using a prescription method among HIVinfected women on ART compared to HIV-infected women not on ART (23.2% vs 35.9%), with a lower proportion of women on ART using SAHC methods compared to women not on ART (11.0% vs 22.7% for ART and non-ART, respectively). There was increased LARC use among ART users from 2008 through 2014. In both the ART and no ART groups, there were more women using prescription method in 2014 compared to 2008, although this difference was not statistically significant.
Results of the multivariable polytomous regression models evaluating contraceptive use are reported in Table 4 . There were lower odds of LARC method (aOR, 0.67; 95% CI, 0.52e0.86 vs no prescription method) and SAHC method use (aOR, 0.59; 95% CI, 0.50e0.70 vs no prescription method) 
Comment
Our study evaluating a large national database of privately insured women highlights the persistent discrepancy in contraceptive use for HIV-infected women compared to noninfected women in the United States. While prior studies demonstrated an encouraging increase in the use of more effective LARC contraceptives 10 among noninfected women, our report also suggests this trend may be occurring among HIVinfected women, a finding that differs from prior reports. 2 Despite this improvement in overall effective contraceptive use, our results show that reliance on no prescription method or female sterilization is more common among women with HIV compared with uninfected women. Prior research similarly found that HIV-infected women often rely on nonprescription contraceptive methods, such as condoms. 11 As the pregnancy rates with typical condom usage are as high as 15% in the first year of use, 12 current recommendations emphasize the need for dual protection, simultaneous use of a second more effective method of contraception (sterilization, LARC, or SAHC) in addition to condoms for sexually transmitted infection and HIV prevention. Our data indicate that the reliance on lower efficacy nonprescription contraceptive methods or no method persists despite these current dual-method recommendations. Given the high rates of unintended pregnancy in the United States, which are associated with negative health consequences, along with risks associated with pregnancy among HIVinfected women, efforts should be directed at increasing use of effective contraception beyond condoms alone among HIV-infected women as well. 13 Further, since those in our study with HIV are older with more chronic medical conditions, contraceptive use to reduce the risks associated with unintended pregnancy should be emphasized. A recent study demonstrates that despite decreasing rates of induced abortion nationally, such rates among HIV-infected women have remained stable, 13 suggesting that prevention of unintended pregnancy has not improved overall reproductive outcomes for women with HIV.
Our data highlight that those with HIV are about 40% less likely to use SAHC compared to noninfected women. Lower use of these contraceptives among women with HIV may be related to providers' concerns about the safety of certain methods for women with HIV. However, evidence has not demonstrated that hormonal contraceptives are associated with HIV disease progression or HIV transmission to uninfected male partners. 14 Our findings also highlight that among women with HIV, those using ART have about 50% lower odds of using SAHC than those not using ART. This may be related to ongoing concerns regarding the safety of combining certain hormonal contraceptive methods with antiretroviral drugs given concerns for drug-drug interactions reducing the effectiveness of either the birth control or ART. However, HIV-infected women should be reassured that studies have found few interactions between hormonal contraceptives and antiretroviral drugs that limit their use. Even in cases where a drug interaction may exist, studies suggested the impact could lead to a reduction in contraceptive but not antiretroviral effectiveness. [15] [16] [17] In these situations, such as the case of efavirenzbased regimens used with an etonogestrel or levonorgestrel contraceptive implant, the implant effectiveness is often still superior to nonprescription contraceptive alternatives. 18 Further, in cases where a provider may be concerned or unfamiliar with the potential drugdrug interactions, alternative forms of effective contraception, such as the nonhormonal IUD, can be considered. Health care providers should counsel women about the overall safety of contraceptives used in conjunction with ART, present a broad spectrum of contraceptive options available to avoid potential drug interactions, and not be hesitant to provide hormonal contraception, especially LARC, to women on ART.
We did not find a difference in the rates of sterilization among women with HIV compared to noninfected women. This is contrary to reports from earlier in the HIV epidemic when women reportedly felt pressure to undergo sterilization, and, even in cases when sterilization was not coerced, many experienced subsequent regret. 19 Our findings support an encouraging change toward increased reproductive choice for HIV-infected women.
As ART use increases and health status improves, recent data suggest that HIVinfected women have desires for children and pregnancy rates similar to noninfected women. 20 ART users should receive regular clinical care, thus offering numerous opportunities to address their contraceptive needs. Unfortunately, family planning is often absent from the current HIV clinical care paradigm. This integration of services is essential if we hope to adequately address the robust reproductive health needs of women living with HIV. Efforts must focus on understanding reproductive health needs of this cohort and providing targeted family planning options within an integrated care framework. Our study has several strengths as well as some limitations. With use of this large claims data set, we are able to evaluate a nationwide sample of privately insured women living with HIV compared to noninfected women as well as evaluate the change in patterns over time. Further, by controlling for other medical conditions that may influence contraceptive prescription patterns, we are able to more specifically determine the impact of HIV on contraceptive use. While our data are representative of a nationwide privately insured population, they may not be generalizable to ajog.org
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Medicaid or uninsured populations. As a significant proportion of women with HIV rely on Medicaid or are uninsured, we may not be able to extrapolate these findings to all HIV-infected women. However, it is notable that women continuously enrolled in these health care plans should have similar access to contraceptives and thus any differences detected likely reflect true practice pattern differences within the cohort of women who are insured. While we demonstrate an overall improvement in contraceptive use over time, the impact of the Affordable Care Act, passed in 2010, on access to contraception may account for some of these observed patterns. The small number of HIVinfected women, particularly ART users, may have reduced our power to detect differences between groups. As with any administrative database, there are inherent risks of misclassification. We aimed to reduce misclassification by using more conservative definitions for defining diagnoses, including 2 outpatient visits, rather than 1. Further, while we aimed to capture contraceptive and surgical procedures for individuals over a continuous time frame of 6 years for each cohort, we may have not captured sterilization procedures or IUD insertions performed outside of the study interval. Additionally, prescriptions may not reflect actual use of the contraceptive. This is particularly important for user-dependent methods such as combined hormonal contraceptive pills, where individuals may incorrectly, infrequently, or never use the method prescribed. Women classified as nonusers may have included those with IUD insertion, sterilizations, or hysterectomy before 2004; women relying on male sterilization or using nonprescription methods (barrier methods or fertility awareness-based methods); or women who were pregnant, trying to become pregnant, not sexually active, or otherwise not at risk for unintended pregnancy. Lastly, we captured only prescription and surgical contraceptive methods and cannot specifically comment on the use of nonprescription methods, such as condoms. This underscores that certain women may be relying on no method or condom use alone, rather than a more effective prescription methods of birth control. Providers need to counsel patients on the use of more highly effective prescription contraceptive methods, beyond condom use. For HIV-infected individuals specifically, providers must go beyond condom promotion to emphasize dualmethod use with combining condoms, for HIV and sexually transmitted infection prevention, along with prescription contraceptive use, for pregnancy prevention.
In conclusion, our data highlight a persistent gap in effective contraceptive use among women with HIV in the United States compared to HIVuninfected women. We should aim to better understand the reasons for lower use of LARC and SAHC methods and further promote effective contraceptives. Future efforts should focus on increasing dual-method contraceptive use while educating patients and providers regarding potential misconceptions that could limit contraceptive use. Our findings emphasize the importance of understanding the reproductive health needs of women living with HIV and providing targeted family planning options as part of routine HIV care. 
